Literature DB >> 32701583

Elevation of cervical C-X-C motif chemokine ligand 10 levels is associated with HIV-1 acquisition in pregnant and postpartum women.

Michelle C Sabo1, Dara A Lehman2,3, Jillian C Pintye2, Bingjie Wang3, Alison L Drake2, John Kinuthia2,4, Lusi Osborn5, Daniel Matemo5, Barbra A Richardson2,6,7, Julie Overbaugh7, Grace John-Stewart1,2,8,9, Susan M Graham1,2,8.   

Abstract

OBJECTIVE: To evaluate the relationship between cervical cytokine/chemokine concentrations and HIV-1 acquisition in peripartum Kenyan women.
DESIGN: Nested case-control study.
METHODS: Women participating in a prospective study of peripartum HIV acquisition in Kenya (the Mama Salama Study), were tested for HIV-1 at 1-3 month intervals during pregnancy and through 9 months postpartum. Cases positive for HIV-1 RNA during follow-up (N = 14), were matched 3 : 1 with HIV-negative controls (N = 42) based on age, marital status, partner HIV-1 status, transactional sex, and timing of cervical swab collection. Concentrations of five cytokines (IL-1β, IL-6, IL-10, IFNγ, and TNFα) and four chemokines (IL-8, C-X-C motif chemokine ligand 10 (CXCL10), macrophage inflammatory protein-1 α, and macrophage inflammatory protein-1 β) were measured from cervical swabs collected at the visit prior to HIV-1 diagnosis (cases) or matched gestational/postpartum time (controls). Cytokine/chemokine concentrations were compared between cases and controls using Wilcoxon rank-sum tests. Principal component analysis was used to create a summary score for closely correlated cytokines/chemokines. Associations with HIV-1 acquisition were analyzed using conditional logistic regression. Path analysis was used to evaluate hypothesized relationships between CXCL10, vaginal washing, Nugent score, and HIV-1 acquisition.
RESULTS: Conditional logistic regression analysis demonstrated an association between increased concentrations of CXCL10 and HIV-1 acquisition (odds ratio = 1.74, 95% confidence interval 1.04, 2.93; P = 0.034). Path analysis confirmed a positive independent association between higher concentrations of CXCL10 and HIV-1 acquisition (path coefficient = 0.37, 95% confidence interval 0.15, 0.59; P < 0.001).
CONCLUSION: HIV-1 acquisition was associated with increased cervical concentrations of CXCL10 in pregnant and postpartum women.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32701583      PMCID: PMC7964249          DOI: 10.1097/QAD.0000000000002613

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  41 in total

1.  Antimicrobial factors in the cervical mucus plug.

Authors:  Merete Hein; Erika V Valore; Rikke Bek Helmig; Niels Uldbjerg; Tomas Ganz
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

2.  Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus.

Authors:  David J Sharkey; Kelton P Tremellen; Melinda J Jasper; Kristina Gemzell-Danielsson; Sarah A Robertson
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

Review 3.  Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies.

Authors:  Julius Atashili; Charles Poole; Peter M Ndumbe; Adaora A Adimora; Jennifer S Smith
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

4.  Genital inflammation and the risk of HIV acquisition in women.

Authors:  Lindi Masson; Jo-Ann S Passmore; Lenine J Liebenberg; Lise Werner; Cheryl Baxter; Kelly B Arnold; Carolyn Williamson; Francesca Little; Leila E Mansoor; Vivek Naranbhai; Douglas A Lauffenburger; Katharina Ronacher; Gerhard Walzl; Nigel J Garrett; Brent L Williams; Mara Couto-Rodriguez; Mady Hornig; W Ian Lipkin; Anneke Grobler; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

5.  Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion.

Authors:  Charles Morrison; Raina N Fichorova; Chris Mauck; Pai-Lien Chen; Cynthia Kwok; Tsungai Chipato; Robert Salata; Gustavo F Doncel
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

6.  Associations between vaginal bacteria implicated in HIV acquisition risk and proinflammatory cytokines and chemokines.

Authors:  Michelle C Sabo; Dara A Lehman; Bingjie Wang; Barbra A Richardson; Sujatha Srinivasan; Lusi Osborn; Daniel Matemo; John Kinuthia; Tina L Fiedler; Matthew M Munch; Alison L Drake; David N Fredricks; Julie Overbaugh; Grace John-Stewart; R Scott McClelland; Susan M Graham
Journal:  Sex Transm Infect       Date:  2019-06-13       Impact factor: 3.519

7.  Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples.

Authors:  Erin M Kahle; Michael Bolton; James P Hughes; Deborah Donnell; Connie Celum; Jairam R Lingappa; Allan Ronald; Craig R Cohen; Guy de Bruyn; Youyi Fong; Elly Katabira; M Juliana McElrath; Jared M Baeten
Journal:  J Infect Dis       Date:  2014-11-10       Impact factor: 5.226

8.  Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples.

Authors:  Nelly R Mugo; Renee Heffron; Deborah Donnell; Anna Wald; Edwin O Were; Helen Rees; Connie Celum; James N Kiarie; Craig R Cohen; Kayitesi Kayintekore; Jared M Baeten
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

9.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

10.  Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.

Authors:  R N Fichorova; M Bajpai; N Chandra; J G Hsiu; M Spangler; V Ratnam; G F Doncel
Journal:  Biol Reprod       Date:  2004-05-05       Impact factor: 4.285

View more
  1 in total

1.  Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.

Authors:  Eric Armstrong; Anke Hemmerling; Steve Miller; Kerianne E Burke; Sara J Newmann; Sheldon R Morris; Hilary Reno; Sanja Huibner; Maria Kulikova; Nico Nagelkerke; Bryan Coburn; Craig R Cohen; Rupert Kaul
Journal:  Lancet Microbe       Date:  2022-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.